CRIM1

Across TCGA pan-cancer cohorts, CRIM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRIM1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CRIM1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CRIM1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where CRIM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.307	0.843	<.001	48	view →
HNSC	DFS	Median	III,IV	1.000	0.913	.010	13	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.617	.033	12	view →
CCRCC	DFS	Quartile	All	0.589	0.834	.027	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRIM1–LUAD (OS)

Open the LUAD breakdown →